Here's why Eli Lilly stock is crashing

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations.The pharmaceutical giant now projects $13.5 billion in revenue for the quarter, sparking concerns over the performance of its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.As of the market close on January 14, Eli Lilly’s stock was trading at $744.91, reflecting a one-day loss of over 6.5%. On the five-d ...